The safety of pneumococcal vaccines at the time of sequential schedule: data from surveillance of adverse events following 13-valent conjugated pneumococcal and 23-valent polysaccharidic pneumococcal vaccines in newborns and the elderly, in Puglia (Italy)
Keywords:
AEFIs, causality assessment, PCV13, PPSV23, vaccinationAbstract
Background. Nowadays, two types of anti-pneumococcal vaccine are available: pneumococcal 13-valent conjugate vaccine (PCV13), first licensed in the United States (US) in 2013, and pneumococcal 23-valent polysaccaridic vaccine (PPSV23), first licensed in the US in 1999. These vaccines are recommended in Italy for the immunization of newborns and of the elderly, using a combined sequential schedule for the latter. This report aims to describe the PCV13- and PPSV23-related AEFIs notified in Puglia in 2013-2020, in order to design these products’ safety profile in a real-life scenario, three years after the official recommendation about the sequential schedule for people over 60 years of age.
Methods. This is a retrospective observational study. Data were gathered from the list of AEFIs notified following PCV13 and PPSV23 administration in Puglia in 2013-2020. The number of administered vaccine doses was obtained from the regional immunization database. AEFIs were classified according to WHO’s algorithm, and causality assessment was carried out in case of serious AEFIs.
Results. From January 2013 to December 2020, 764,183 doses of PCV13 and 40,382 doses of PPSV23 were administered in Puglia. In the same period, 71 PCV13 AEFIs (Reporting Rate: 9.29 x100,000 doses) and 5 PPSV23 AEFIs (Reporting Rate: 12.4 x100,000 doses) were reported.
The overall male/female ratio in AEFIs was 0.85. The majority of AEFIs occurred in subjects aged less than 2 (64/76, 84.2%), while 10 out of 76 (13.2%) occurred in patients aged 60 or older. 22 AEFIs were classified as serious and for 12 (54.5%) causality assessment showed a consistent relationship with immunization. The most commonly reported symptoms were fever (Reporting Rate: 4.72 x100,000 doses) and neurological symptoms (Reporting Rate: 3.23 x100,000 doses). Only one death was notified, classified as non-vaccinerelated.
Conclusions. The benefit of pneumococcal vaccination appears to be greater than the risk of AEFIs for both PCV13 and PPSV23. In fact, AEFIs occur in less than 0.1‰ of patients and the majority of AEFIs are mild and self-limiting.
References
1. Dion CF, Ashurst JV. Streptococcus Pneumoniae. 2021 Aug 11. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan–. PMID: 29261971.
2. Tereziu S, Minter DA. Pneumococcal Vaccine. 2021 Apr 19. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan–. PMID: 29939571.
3. Matanock A, Lee G, Gierke R, Kobayashi M, Leidner A, Pilishvili T. Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged ≥65 Years: Updated Recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep. 2019 Nov 22; 68(46): 1069-1075. doi: 10.15585/ mmwr.mm6846a5. Erratum in: MMWR Morb Mortal Wkly Rep. 2020 Jan 3; 68(5152): 1195. PMID: 31751323; PMCID: PMC6871896.
4. Berical AC, Harris D, Dela Cruz CS, Possick JD. Pneumococcal Vaccination Strategies.
An Update and Perspective. Ann Am Thorac
Soc. 2016 Jun; 13(6): 933-44. doi: 10.1513/ AnnalsATS.201511-778FR. PMID: 27088424; PMCID: PMC5461988.
5. Lin PL, Michaels MG, Green M, et al. Safety and immunogenicity of the American Academy of Pediatrics--recommended sequential pneumococcal conjugate and polysaccharide vaccine schedule in pediatric solid organ transplant recipients. Pediatrics. 2005 Jul; 116(1): 160-7. doi: 10.1542/peds.2004-2312. PMID: 15995047.
6. Rose MA, Gruendler M, Schubert R, Kitz R, Schulze J, Zielen S. Safety and immunogenicity of sequential pneumococcal immunization in preschool asthmatics. Vaccine. 2009 Aug 20; 27(38): 5259-64. doi: 10.1016/j.vaccine.2009.06.054. Epub 2009 Jul 2. PMID: 19576944.
7. World Health Organization (WHO). Causality assessment of an adverse event following immunization (AEFI): user manual for the revised WHO classification. 2nd ed., 2019 update. Available on: https://www.who.int/publications/i/ item/9789241516990 [Last accessed: 2022 October 25].
8. Stefanizzi P, De Nitto S, Spinelli G, et al. Post-Marketing Active Surveillance of Adverse Reactions Following Influenza Cell-Based Quadrivalent Vaccine: An Italian Prospective Observational Study. Vaccines (Basel). 2021 May
4; 9(5): 456. doi: 10.3390/vaccines9050456. PMID: 34064483; PMCID: PMC8147936.
9. Tafuri S, Fortunato F, Gallone MS, et al. Systematic causality assessment of adverse events following HPV vaccines: Analysis of current data from Apulia region (Italy). Vaccine. 2018 Feb 14; 36(8): 1072-77. doi: 10.1016/j.vaccine.2018.01.018. Epub 2018 Jan 19. PMID: 29358055.
10. Tafuri S, Gallone MS, Calabrese G, Germinario C. Adverse events following immunization: is this time for the use of WHO causality assessment? Expert Rev Vaccines. 2015 May; 14(5): 625-7. doi: 10.1586/14760584.2015.1029460. Epub 2015 Mar 25. PMID: 25805053.
11. Bonanni P, Villani A, Scotti S, et al. The recommended lifetime immunization schedule from the board of vaccination calendar for life in Italy: A continuing example of impact on public health policies. Vaccine. 2021 Feb 22; 39(8): 1183-6. doi: 10.1016/j.vaccine.2021.01.019. PMID: 33589048.
11. Regione Puglia. Calendario vaccinale per la vita 2018; 2019 Feb 7. Available on: https://www. sanita.puglia.it/documents/20182/26673928/ Calendario+vaccinale+per+la+vita+2018/ f36429b9-5f76-44c2-b495-d5b9228959ef?ve rsion=1.0&t=1549553827908 [Last accessed: 2022 October 25].
12. Agenzia Italiana del Farmaco (AIFA) - Gruppo di Lavoro sull’analisi dei segnali dei vaccini. Guida alla valutazione delle reazioni avverse osservabili dopo vaccinazione. 2016. Available
on: http://www.aifa.gov.it/sites/default/files/ Guida_valutazione_reazioni_avverse_osservabili_dopo_vaccinazione_2.pdf [Last accessed: 2022 October 25].
13. European Medicines Agency (EMA). Important medical event terms list version (MedDRA) - version 24.0. Available on: https://www.ema. europa.eu/en/human-regulatory/researchdevelopment/pharmacovigilance/eudravigilance/eudravigilance-system-overview [Last accessed: 2022 October 25].
14. Stefanizzi P, Stella P, Ancona D, et al. Adverse
Events Following Measles-Mumps-RubellaVaricella Vaccination and the Case of Seizures: A Post Marketing Active Surveillance in
Puglia Italian Region, 2017-2018. Vaccines
(Basel). 2019 Oct 7; 7(4): 140. doi: 10.3390/ vaccines7040140. PMID: 31591347; PMCID: PMC6963278.
15. European Medicines Agency (EMA). Prevenar 13. Summary of product characteristics. 2015. Available on: https://www.ema.europa.eu/en/ medicines/human/EPAR/prevenar-13 [Last accessed: 2022 October 25.
16. U.S. Food and Drug Administration. Pneumovax 23. Summary of product characteristics. 2020. Available on: https://www.fda.gov/media/80547/ download [Last accessed: 2022 October 25].
17. Jackson LA, Gurtman A, van Cleeff M, et al. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults. Vaccine. 2013 Aug 2; 31(35): 3577-84. doi:
10.1016/j.vaccine.2013.04.085. Epub 2013 May
18. PMID: 23688526.
18. Agier MS, Marchand S, Paret N, Gautier S, Jonville-Béra AP. Bilan français des effets indésirables du vaccin Prévenar 13® [Postlicensure safety surveillance for Prevenar 13® in France]. Arch Pediatr. 2017 May; 24(5): 43944. French. doi: 10.1016/j.arcped.2017.01.018. Epub 2017 Feb 24. PMID: 28242152; PMCID: PMC7133411.
19. Stefanizzi P, De Nitto S, Patano F, et al. Postmarketing surveillance of adverse events following measles, mumps, rubella and varicella (MMRV) vaccine: retrospecive study in apulia region (ITALY), 2009-2017. Hum Vaccin Immunother. 2020 Aug 2; 16(8): 1875-83. doi:
10.1080/21645515.2019.1704124. Epub 2020 Feb
10. PMID: 32040350; PMCID: PMC7482746.
20. Tafuri S, Gallone MS, Cappelli MG, Martinelli D, Prato R, Germinario C. Addressing the antivaccination movement and the role of HCWs. Vaccine. 2014 Aug 27; 32(38): 4860-5. doi:
10.1016/j.vaccine.2013.11.006. Epub 2013 Nov
18. PMID: 24262311.
21. Faranda D, Alberti T, Arutkin M, Lembo V, Lucarini V. Interrupting vaccination policies can greatly spread SARS-CoV-2 and enhance mortality from COVID-19 disease: The AstraZeneca case for France and Italy. Chaos. 2021 Apr; 31(4): 041105. doi: 10.1063/5.0050887.
PMID: 34251248.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.